The purpose of this research was to investigate the relationship between epidermal growth factor receptor (EGFR) mutations and the response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 266 patients with stage IIIB or IV NSCLC who received platinum-based doublet therapies as first-line chemotherapy were investigated retrospectively, and their clinical data were assessed according to EGFR mutation. Results: EGFR mutations were identified in 45.5% of patients. There was no significant difference in response rate between EGFR mutation carriers and EGFR wild-type carriers (P=0.484). Among the patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type, however, those with EGFR mutations responded better to treatment than EGFR wild-type patients (46.2% versus 20.8%, P=0.043). The disease control rate associated with pemetrexed-based treatments was higher than for vinorelbine-based therapies in EGFR mutation patients (P=0.001). EGFR mutation was found in patients with longer progression-free survival and median survival time, and improved 1-year and 2-year overall survival when compared with EGFR wild-type patients (6.1 versus 5.0 months, P=0.004; 18.9 versus 13.8 months, P=0.001; 81.0% versus 63. 4%, P=0.002; and 33.9% versus 22.8% P=0.044, respectively). Patients with the EGFR exon 19 mutation had longer progression-free survival than those with EGFR exon 21 mutation (P=0.007). Multivariate analysis showed that the response to first-line chemotherapy and the presence of EGFR mutations were independent prognostic factors in patients with advanced NSCLC. Conclusion: Our data showed that the presence of EGFR mutations meant longer survival times for patients with advanced NSCLC who received platinum-based doublet first-line chemotherapy, especially in those with the exon 19 deletion mutation. Among KRAS wild-type patients, those with EGFR mutation responded better to first-line chemotherapy than EGFR wild-type patients.
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Introduction
Lung cancer continues to be the main cause of carcinoma-related death throughout the world, 1 and 75%-80% of these cancers are non-small cell lung cancer (NSCLC). 2 Although surgery is the most effective treatment for NSCLC, about 70% of patients with NSCLC miss the opportunity for surgical resection because of their advanced disease at presentation. 3 Chemotherapy is the preferred treatment for these patients. There has been research showing that NSCLC patients with the epidermal growth factor receptor (EGFR) mutation respond better to EGFR tyrosine kinase inhibitors (TKIs) in terms of long-term survival. 4 Several Phase III clinical trials also indicated that NSCLC patients with mutated EGFR had better clinical outcomes from treatment with erlotinib or gefitinib than from normal chemotherapy. [5] [6] [7] At present, EGFR is the primary predictor of a curative effect of EGFR TKIs, and the relevant research [8] [9] [10] has shown that the mutation status of EGFR is probably the main determinant of response to first-line chemotherapy and the prognosis in patients with advanced NSCLC.
The standard first-line regimen for advanced NSCLC is platinum-based doublet chemotherapy. 11, 12 Common chemotherapeutic agents are gemcitabine, docetaxel, vinorelbine, and pemetrexed, but there continues to be a lack of predictive biomarkers to select drugs for first-line chemotherapy. On this background, we reviewed the clinical outcomes in patients with advanced NSCLC who received platinum-based doublet therapies as first-line chemotherapy, and analyzed the predictive value of EGFR mutation status with regard to short-term effects and long-term survival in order to optimize the treatment of individual patients with advanced NSCLC.
Patients and methods Patients
A total of 665 cases of stage IIIB or IV NSCLC treated at Shandong Tumor Hospital from July 2008 to December 2011 were screened, and 266 who received platinum-based doublet chemotherapy as their first-line treatment were analyzed retrospectively. These patients satisfied the following selection criteria: having a pathological diagnosis of NSCLC, clear EGFR mutation status, platinum-based doublet first-line chemotherapy for at least two cycles, measurable lesions, no uncontrolled diabetes or other serious disease, and an Eastern Cooperative Oncology Group performance status of 0-1. 13 
EGFR mutation analysis
Sequence analysis of EGFR exons 18-21 was done by pyrosequencing, as described elsewhere.
14 Briefly, the presence of tumor cells was identified on sections stained with hematoxylin and eosin. Formalin-fixed paraffin-embedded tissue samples were microdissected to confirm that the samples contained not less than 80% tumor cells. Xylene and ethanol were used to remove paraffin from the tumor tissues, and the samples were placed in proteinase K. Genomic DNA was extracted using a QIAamp DNA formalin-fixed paraffin-embedded tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Subsequently, EGFR exons 18-21 were amplified by nested polymerase chain reaction and subjected to pyrosequencing. The polymerase chain reaction products were analyzed by electrophoresis in 3% agarose gel to confirm successful amplification. The pyrosequencing assay was performed using the PyroMark Q24 ID system (Qiagen) following the manufacturer's protocols. Samples harboring mutations were resequenced using the same test conditions.
evaluation methods
Based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines, 15 the response to treatment was classified as a complete response, partial response, stable disease, or progression of disease. Complete response and partial response were defined as the response rate, and complete response, partial response, and stable disease were defined as the disease control rate.
Follow-up
Follow-up was undertaken in all patients. The last follow-up was in January 2014, and the median duration of follow-up was 25.1 months. Overall survival was defined as the time from the date of receiving the first-line chemotherapy to death or last follow-up. Progression-free survival was defined as the time from the date of receiving the first-line chemotherapy to disease progression or death.
statistical analysis
The statistical analysis was performed using Statistical Package for the Social Sciences version 17.0 software (SPSS Inc., Chicago, IL, USA). Rates were compared using the χ 2 test. Fisher's exact test was used to analyze categorical variables. Median progression-free survival was calculated using the Kaplan-Meier method. The Cox regression model was used to identify independent prognostic factors for advanced NSCLC. We used the Kaplan-Meier method to draw survival curves and tested these by log-rank. Twosided P-values ,0.05 were considered to be statistically significant.
Results
Patient characteristics
Patient characteristics are shown in Table 1 . The research cohort comprised 266 NSCLC patients of median age 57 (range 28-81) years, with 53.4% being male. One hundred and eighty patients had stage IV disease (67.7%), and 242 had adenocarcinoma (91.0%). The most common Table 2 .
relationship between EGFR mutation and survival
The median progression-free survival for the 266 patients was 5.7 months (95% confidence interval [CI] 5.4-6.0), the median survival time was 16.8 months, and the 1-year and 2-year overall survival was 72.2% and 28.6%, respectively. There was a significant difference in progression-free Table 3 .
In EGFR wild-type patients, there were no statistically significant differences in progression-free survival between the gemcitabine-based, docetaxel-based, vinorelbine-based, and pemetrexed-based treatments (5.7 months versus 4.6, 5.6, and 4.9 months, respectively, P=0.946, Figure 3) . Further, there was no statistically significant difference in progressionfree survival between the four treatment groups in patients with EGFR mutation (6.0 months versus 6.3, 6.4, and 5.9 months, P=0.814, Figure 4 ).
Univariate analysis of various prognostic factors, and the data showed that the important ones were clinical stage (P=0.001), response to first-line chemotherapy (P=0.001), histological type (P=0.008), whether TKIs were received after first-line chemotherapy (P=0.023), and EGFR mutation status (P=0.001). Cox multivariate regression analysis was used to determine underlying factors influencing survival, eg, age, sex, smoking history, Eastern Cooperative Oncology Group status, histological diagnosis, weight loss, whether TKIs are received after first-line chemotherapy, tumor stage, EGFR mutation, 
Figure 3
Kaplan-Meier estimates of progression-free survival for gemcitabinebased, docetaxel-based, vinorelbine-based, and pemetrexed-based treatments in wild-type EGFR patients. Note: Kaplan-Meier analysis showed that there were no statistically significant differences in progression-free survival among gemcitabine-based, docetaxel-based, vinorelbine-based, and pemetrexed-based treatments in wild-type EGFR patients (5.7 versus 4.6 versus 5.6 versus 4.9, P=0.946). Abbreviation: EGFR, epidermal growth factor receptor. 
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Fang et al and the efficacy of first-line chemotherapy. The results showed that response to front-line chemotherapy and EGFR mutation status were independent prognostic factors (Table 4) . Figure 5 ).
relationship between EGFR mutation and response to second-line treatment 
Discussion
These data show that active EGFR mutations portend a longer survival time in patients with advanced NSCLC, especially those with the exon 19 mutation. KRAS wildtype patients with the EGFR mutation responded better to first-line chemotherapy, and EGFR mutation and curative first-line chemotherapy were independent prognostic factors for advanced NSCLC. Platinum-based doublet chemotherapy is presently the most common first-line treatment for advanced NSCLC. 11, 12 Therefore, it is important to explore the relationship between EGFR mutation, effect of chemotherapy, and clinical outcome. The relationship between EGFR mutation status and response to chemotherapy is not well understood. Kalikaki et al 16 reported that chemotherapy was more effective in patients with EGFR mutation than in EGFR wild-type patients (P=0.023). The Iressa Pan-Asia Study 17 indicated that the response rate was higher in the patients with EGFR mutations compared with wild-type EGFR cases who received paclitaxel/carboplatin as the first-line chemotherapy (47.3% versus 23.5%). A study reported by Lee et al 9 found no obvious relationship between presence of EGFR mutation and the effectiveness of first-line chemotherapy. However, a recent Japanese study indicated that patients with the EGFR mutation were less sensitive to docetaxel than those with wild-type EGFR. 10 Our study showed that the response rate and disease control rate of the first-line chemotherapy platinum containing regimens were both higher in patients with the EGFR mutation than in patients with EGFR wild-type in advanced NSCLC. No statistically significant differences were found between these two groups, which is probably due to the small sample size. However, we did find that patients with the 18 showed that patients with the KRAS mutation had shorter survival than their KRAS wild-type counterparts, suggesting that KRAS mutation and EGFR mutation might have opposing effects. Both the EGFR and KRAS genes predict the prognosis of NSCLC. 19, 20 Exon 19 deletion mutation and a mutation in exon 21 (L858R) are the two main types of EGFR mutation. Riely et al 21 found that patients with the EGFR exon 19 mutation had a longer median survival time than those with the EGFR exon 21 mutation after receiving gefitinib or erlotinib (34 versus 8 months, respectively; P=0.01, log-rank). Park et al 22 investigated 217 patients with NSCLC and found that those with EGFR mutations who received paclitaxel had a better disease control rate and longer progression-free survival, which was more pronounced in patients with the exon 19 deletion mutation. Cappuzzo et al 8 found no clear relationship between EGFR mutation status and the effectiveness of first-line chemotherapy, but patients with the exon 19 mutation showed a higher objective response rate after receiving chemotherapy (46.6% versus 0%, P=0.02). Our research also indicates that patients with the exon 19 deletion mutation had a longer survival time after first-line platinum-based chemotherapy than those with the exon 21 mutation (P=0.007). Further, the effectiveness of first-line chemotherapy was greater in patients with the exon 19 mutation than in those with the exon 21 mutation (37.5% versus 24.0%, P=0.124), but the difference was not statistically significant.
Pemetrexed is a new-generation multitargeted antifolate agent that maintains tumor cell division in S phase by destroying the folate-dependent metabolic pathway within the cells, thereby limiting tumor growth. 23 Pemetrexed is now the preferred second-line treatment for NSCLC in the USA. 24 In recent years, clinical researchers had demonstrated the positive effects of this agent in advanced NSCLC, and pemetrexed has gradually become a first-line agent for treatment of the disease. 23 Meanwhile, there is some prospective and retrospective evidence 25, 26 from Phase III research showing longer overall survival in patients with nonsquamous NSCLC treated with pemetrexed than in their counterparts treated with gemcitabine or docetaxel. These observations indicate that pemetrexed had higher activity in nonsquamous cell cancer. In the present study, we found that the disease control rate was higher for pemetrexed-based chemotherapy than for vinorelbine-based chemotherapy in patients with EGFR mutation. However, we cannot conclude that EGFR mutation improves the sensitivity to pemetrexed, because our results might have arisen from the fact that the majority of our patients with the EGFR mutation had adenocarcinoma of the lung (96.7%, 117/121) and pemetrexed has been shown to be more effective than other chemotherapeutic agents in this type of cancer. 25, 26 Our retrospective analysis has some limitations, and there remains a need for prospective research in large samples to resolve whether EGFR mutation could improve the sensitivity to pemetrexed in advanced NSCLC patients.
Our analysis of survival in 266 patients with NSCLC indicates that those with EGFR mutations had longer progression-free survival than those with wild-type EGFR. This finding is similar to that of Hotta et al, 27 who analyzed survival data in 194 patients and found that patients with EGFR mutation had longer progression-free survival. However, other researchers have reported that EGFR mutation status has no impact on the effect of chemotherapy or longterm survival. 9 The current research analyzed the relationship between EGFR mutation status and progression-free survival, and indicated that EGFR mutation had a greater survival benefit when compared with wild-type status (P=0.004). Multifactorial analysis revealed that EGFR mutation and efficacy of first-line chemotherapy were independent prognostic factors in patients with advanced NSCLC, which is consistent with the results of other research. 
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Fang et al Currently, the international recommendations for secondline treatment are docetaxel, pemetrexed, and EGFR TKIs. One hundred and forty-six patients were included in the Phase III INTEREST (Gefitinib versus docetaxel in previously treated non-small-cell lung cancer) trial, 29 the main aim of which was to compare overall survival between gefitinib and docetaxel by testing for noninferiority. Overall survival was 7.6 months in the gefitinib group and 8.0 months in the docetaxel group, and the 1-year survival rate was 32% and 34%, respectively (hazards ratio 1.020, 96% CI 0.905-1.150), which met the preset requirement that the hazards ratio be ,1.154. Gefitinib was significantly higher than that of docetaxel in the quality of life improvement, drug safety, and tolerability. The results of this study, albeit not reaching statistical significance, indicate that survival time in patients with advanced NSCLC is longer with second-line use of EGFR TKIs when compared with conventional chemotherapy.
Conclusion
Our research indicates that active EGFR mutations mean higher survival time for patients with advanced NSCLC who receive platinum-based doublet first-line chemotherapy, especially those with the exon 19 deletion mutation. Among KRAS wild-type patients, those with EGFR mutation responded better to first-line chemotherapy. In this study, EGFR mutation and a curative effect of first-line chemotherapy were independent prognostic factors in advanced NSCLC.
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